Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Habitual coffee consumption and blood pressure: An epidemiological perspective

Authors Johanna M Geleijnse

Published Date August 2008 Volume 2008:4(5) Pages 963—970

DOI http://dx.doi.org/10.2147/VHRM.S3055

Published 5 August 2008

Johanna M Geleijnse

Division of Human Nutrition, Wageningen University, The Netherlands

Abstract: This paper summarizes the current epidemiological evidence on coffee consumption in relation to blood pressure (BP) and risk of hypertension. Data from crosssectional studies suggest an inverse linear or U-shaped association of habitual coffee use with BP in different populations. Prospective studies suggest a protective effect of high coffee intake (4 or more cups per day) against hypertension, mainly in women. Furthermore, the risk of hypertension may be lower in coffee abstainers. Randomized controlled trials, which are mostly of short duration (1–12 weeks), have shown that coffee intake around 5 cups per day causes a small elevation in BP (∼2/1 mmHg) when compared to abstinence or use of decaffeinated coffee. With regard to underlying biological mechanisms, most research has been devoted to BP-raising effects of caffeine. However, there are many other substances in coffee, such as polyphenols, soluble fi bre and potassium, which could exert a beneficial effect in the cardiovascular system. Although the precise nature of the relation between coffee and BP is still unclear, most evidence suggests that regular intake of caffeinated coffee does not increase the risk of hypertension.

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes

Dardano A, Bianchi C, Del Prato S, Miccoli R

Vascular Health and Risk Management 2014, 10:465-475

Published Date: 5 August 2014

Epidemiology of nonfatal stroke and transient ischemic attack in Al-Kharga District, New Valley, Egypt

Farghaly WM, El-Tallawy HN, Shehata GA, Rageh TA, Abdel-Hakeem NM, Elhamed MA, Al-Fawal BM, Badry R

Neuropsychiatric Disease and Treatment 2013, 9:1785-1790

Published Date: 18 November 2013

Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer’s disease models

Bernardi A, Frozza RL, Meneghetti A, Hoppe JB, Battastini AMO, Pohlmann AR, Guterres SS, Salbego CG

International Journal of Nanomedicine 2012, 7:4927-4942

Published Date: 13 September 2012

Validation of reported physical activity for cholesterol control using two different physical activity instruments

Amy Z Fan, Sandra A Ham, Shravani Reddy Muppidi, et al

Vascular Health and Risk Management 2009, 5:649-661

Published Date: 6 August 2009

Risk factors associated with methamphetamine use and heart failure among Native Hawaiians and other Pacific Island peoples

Marjorie K Mau, Karynna Asao, Jimmy Efird, Erin Saito, Robert Ratner, et al

Vascular Health and Risk Management 2009, 5:45-52

Published Date: 7 December 2008

Nonobese, exercising children diagnosed with dyslipidemia have normal C-reactive protein

Miguel Arturo Salazar, Vázquez, Beatriz Yadira Salazar, Vázquez, M Intaglietta, Pedro Cabrales

Vascular Health and Risk Management 2009, 5:65-72

Published Date: 30 September 2008

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes

Marc K Israel, Eva Istvan, Michelle A Baron

Vascular Health and Risk Management 2008, 4:1167-1178

Published Date: 2 September 2008

Clinical efficacy and safety of statins in managing cardiovascular risk

Navin K Kapur, Kiran Musunuru

Vascular Health and Risk Management 2008, 4:341-353

Published Date: 6 May 2008

Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients’ risk level

Daria Roccatagliata, Fausto Avanzini, Lara Monesi, Vittorio Caimi, Davide Lauri, Paolo Longoni, Roberto Marchioli, Massimo Tombesi, Gianni Tognoni, Maria Carla Roncaglioni, on behalf of the Collaborative Group Risk and Prevention Study

Vascular Health and Risk Management 2006, 2:507-514

Published Date: 2 March 2006